ATS View
한국어

Pharmaceutical ingredients Korean listed companies

Grouped by the industry code each company registered with DART. Sorted by latest quarterly operating profit.

한국어
Companies45
Operating profit₩985bnlatest quarter, combined
Operating losses28
Average dividend yield1.6%6 payers

There are 45 KOSPI and KOSDAQ companies classified under pharmaceutical ingredients. Combined operating profit for the latest reported quarter across 45 of them was ₩985bn; 28 posted an operating loss and 1 swung to a profit from a loss a year earlier. The largest by quarterly operating profit were Samsung Biologics, Celltrion and Hugel. The median operating margin across the 37 with reported revenue was -1.6%. 6 paid a cash dividend, with an average reported yield of 1.6%.

Pharmaceutical ingredients companies

CompanyLatest quarter op. profitDividend yieldArticles 30dSignals
Samsung Biologics KOSPI₩586bn
+23% YoY		–380Op. margin 20%+ Insider buying Insider selling Supply contract M&A / stake deal
Celltrion KOSPI₩452bn
+86% YoY		–972Profit +50% Revenue +30% Revenue & profit growth Op. margin 20%+ Share pledge Major holder adding Insider buying Insider selling Buyback Clinical trial filing
Hugel KOSDAQ₩56.0bn
-1% YoY		–47Op. margin 20%+ Insider buying
KolmarBNH KOSDAQ₩10.2bn
-5% YoY		0.5%23Major holder adding Share pledge M&A / stake deal Dividend cut
High Tech Pharm KOSDAQ₩6.3bn
+96% YoY		–2Profit +50% Op. margin 20%+
BioPlus KOSDAQ₩6.2bn
+202% YoY		1.4%20Profit +50% Revenue & profit growth Op. margin 20%+ Major holder adding
Caregen KOSDAQ₩5.2bn
-30% YoY		0.7%4Op. margin 20%+ Insider buying Dividend cut
Medy-Tox KOSDAQ₩4.8bn
-25% YoY		1.0%59–
Bio-fd&c KOSDAQ₩2.1bn
+14% YoY		–2Op. margin 20%+ Share pledge
Aminologics KOSDAQ₩2.0bn–0Op. margin 20%+ Insider selling
Green Lifescience KOSDAQ₩1.8bn–0Revenue +30%
Cell Biotech KOSDAQ₩1.6bn
+28% YoY		4.4%20Revenue +30% Revenue & profit growth
Cellumed KOSDAQ₩1.6bn–0Turnaround
Choong Ang Vaccine Laboratory KOSDAQ₩1.1bn
-24% YoY		–0–
HLB Genex KOSDAQ₩959m
-33% YoY		–17Major holder adding
Kyongbo Pharmaceutical KOSPI₩930m
-61% YoY		–2–
MFC KOSDAQ₩239m–7–
Kolon TissueGene KOSDAQ−₩5m–13Litigation 4 quarters of losses
Olipass KOSDAQ−₩117m–2Delisting / halt risk 4 quarters of losses
NKGen Biotech Korea KOSDAQ−₩130m–8–
BNC Korea KOSDAQ−₩366m
-123% YoY		1.5%14Swung to loss Share pledge 4 quarters of losses
Bio Solution KOSDAQ−₩482m–234 quarters of losses
Naturecell KOSDAQ−₩702m–94 quarters of losses
Kolon Life Science KOSDAQ−₩785m
-162% YoY		–30Swung to loss
Celemics KOSDAQ−₩924m–24 quarters of losses
T&R Biofab KOSDAQ−₩928m–154 quarters of losses
Tego Science KOSDAQ−₩1.2bn–04 quarters of losses
HLB Pep KOSDAQ−₩1.4bn–12Asset deal 4 quarters of losses
Genolution KOSDAQ−₩1.6bn–26Insider buying Major holder adding 4 quarters of losses
iNtRON Biotechnology KOSDAQ−₩1.6bn–114 quarters of losses
Eutilex KOSDAQ−₩2.2bn–04 quarters of losses
QuadMedicine KOSDAQ−₩2.4bn–6Swung to loss Insider buying Clinical trial filing
Xcell Therapeutics KOSDAQ−₩2.8bn–0Insider buying 4 quarters of losses
It-chem KOSDAQ−₩2.8bn–0–
Shaperon KOSDAQ−₩3.1bn–39Insider selling Clinical trial filing Delisting / halt risk 4 quarters of losses
Enzychem Lifesciences KOSDAQ−₩4.1bn–8Revenue +30% Share pledge Litigation 4 quarters of losses
ENCell KOSDAQ−₩4.7bn–174 quarters of losses
Kangstem Biotech KOSDAQ−₩6.1bn–15Clinical trial filing 4 quarters of losses
Peptron KOSDAQ−₩7.9bn–1034 quarters of losses
Genome&Company KOSDAQ−₩8.0bn–384 quarters of losses
Orum Therapeutics KOSDAQ−₩15.4bn–26Insider buying 4 quarters of losses
SK Bioscience KOSPI−₩15.7bn–904 quarters of losses
ABL Bio KOSDAQ−₩16.8bn
-141% YoY		–67Swung to loss Share pledge 4 quarters of losses
Medipost KOSDAQ−₩24.3bn–25M&A / stake deal 4 quarters of losses
Chabiotech KOSDAQ−₩28.2bn–1Share pledge 4 quarters of losses

Industry codes are the primary business each company registered with DART and may not reflect its full business mix. Figures come from DART filings; prices are not included. Not investment advice.